20419-68-5

Basic information

• Product Name: 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
• Synonyms: 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine;2,6-dichloro-9-(oxan-2-yl)-9H-purine
• CAS NO: 20419-68-5
• Molecular Formula: C₁₀H₁₀Cl₂N₄O
• Molecular Weight: 273.12
• Mol File: 20419-68-5.mol
• Article Data: 72

Chemical Properties

• Melting Point: 122-124 °C
• Boiling Point: 417°Cat760mmHg
• Flash Point: 206°C
• Appearance: /
• Density: 1.72g/cm³
• Vapor Pressure: 3.67E-07mmHg at 25°C
• Refractive Index: 1.754
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.38±0.10(Predicted)
• CAS DataBase Reference: 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(20419-68-5)
• EPA Substance Registry System: 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine(20419-68-5)

Safety Data

• Hazardous Substances Data: 20419-68-5(Hazardous Substances Data)

Usage

Uses

2,6-Dichloro-9-(tetrahydropyran-2-yl)-9H-purine is an intermediate in the synthesis of 2,8-Dihydroxyadenine (D450105), a derivative of adenine which accumulates in 2,8-Dihydroxyadenine Urolithiasis.

InChI:InChI=1/C10H10Cl2N4O/c11-8-7-9(15-10(12)14-8)16(5-13-7)6-3-1-2-4-17-6/h5-6H,1-4H2

Upstream product

• 3174-74-1 dihydropyran 
• 5451-40-1 2,6 dichloropurine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 6192-52-5 p-toluenesulfonic acid monohydrate 
• 5451-40-1 2,6-dichloro-7H-purine 
• 142-68-7 TETRAHYDROPYRANE 
• 5451-40-1 2,6-dichloropurine 
• 69-89-6 xanthine 

Downstream Products

• 264608-14-2 2-chloro-N-(2,2-diphenylethyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 28128-30-5 2-methoxy-9H-purin-6-amine 

Relevant articles and documents

Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome

Spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK) are attractive targets in human haematological malignancies with excessively activated B-cell receptor (BCR) signalling pathways. Entospletinib is a SYK inhibitor that has been evaluated as a

Copper-catalyzed N-alkoxyalkylation of nucleobases involving direct functionalization of sp3 CeH bonds adjacent to oxygen atoms

N-Alkoxyalkylation of nucleobases was realized by the copper-catalyzed peroxide-promoted coupling of nucleobases with readily available saturated ethers. Both purines and pyrimidines could be N-alkoxyalkylated through this method in moderate to good yields. 2D-NMR revealed that N9-alkoxyalkylation preferentially occurred when purines were used in this reaction. Crown Copyright

L-ProT catalyzed highly regioselective N-alkoxyalkylation of purine rings with vinyl ethers

An efficient and regioselective synthesis of N-9 alkoxyalkylated purine nucleoside derivatives was achieved via the N-alkoxyalkylation of purine rings with vinyl ethers catalyzed by l-ProT. The advantages of this protocol include good to excellent yield,

Synthesis and photophysical properties of 2-azolyl-6-piperidinylpurines

[Figure not available: see fulltext.] A synthesis of novel fluorescent 2-azolyl-6-piperidinylpurine derivatives was designed. Azolyl substituent at purine C-2 atom was introduced via nucleophilic aromatic substitution or in the case of tetrazolyl and 1,2,3-triazolyl substituents via a ring formation on a preinstalled amine or azide moiety, respectively. The obtained purine intermediates were functionalized at N-9 position using Mitsunobu reaction conditions to achieve amorphous compounds, which form thin-layer films of good quality. The synthesized push-pull systems exhibited fluorescence with emission in range of 360–400 nm and quantum yields up to 66% in CH2Cl2 solution and up to 45% in the thin-layer film.

Purine-aminomethyl-pyridone derivative, preparation method and applications thereof

The invention relates to a purine-aminomethyl-pyridone derivative, a preparation method and applications thereof, and belongs to the field of medicines, and provides a compound represented by a formula I or a pharmaceutically acceptable salt thereof. According to the invention, the pharmacodynamic experiment results prove that the purine-aminomethyl-pyridone derivative can significantly inhibit the proliferation of multiple tumor cells such as colorectal cancer, breast cancer, liver cancer, lung cancer and the like, and has broad-spectrum antitumor effect, and the IC50 values of part of the compounds can reach the nano-mole level wide and are equivalent to the effect of the anti-cancer drug doxorubicin, so that the new choice is provided for development and application of antitumor drugs.